S
SurgiQuest
SurgiQuest - Medical Device Company - AirSeal - AnchorPort
About SurgiQuest
SurgiQuest, Inc. operated as a medical technology firm focused on advancing minimally invasive surgery (MIS). Founded in 2006 by Kurt Azarbarzin, the company was established to address critical limitations in laparoscopic and robotic procedures. Mr. Azarbarzin brought extensive experience to the venture, having previously served in high-level research and development roles at United States Surgical Corporation, a pioneer in surgical devices. Many of SurgiQuest's executives also came from United States Surgical Corporation, providing a deep institutional knowledge base from the outset.
The company's core business involved the development, manufacturing, and marketing of access technologies for surgeons. Its business model centered on selling its proprietary AirSeal® System to hospitals and surgical centers, which catered to specialties like general surgery, gynecology, and urology. The venture was backed by several investment firms, including River Cities Capital and Fletcher Spaght, raising approximately $59.1 million over seven funding rounds to fuel its growth and product development.
SurgiQuest's flagship product, the AirSeal® System, was an integrated platform for managing surgical access. Unlike conventional trocars and insufflation systems, AirSeal provided a valve-free access port with an intelligent flow system. This technology created a stable pneumoperitoneum (an insufflated abdomen), offered continuous smoke and plume evacuation, and allowed for valve-free instrument access during procedures. Clinical data demonstrated that the use of AirSeal led to shorter procedure times and reduced post-operative pain. By the end of 2015, the system had been used in over 340,000 procedures worldwide.
A significant milestone in the company's history was its acquisition by CONMED Corporation (NASDAQ: CNMD). In November 2015, CONMED announced a definitive agreement to acquire SurgiQuest for $265 million, a deal that was completed in January 2016. At the time of the acquisition, SurgiQuest was on a strong growth trajectory, with projected revenues of $55 to $60 million for 2016. Following the acquisition, Kurt Azarbarzin joined CONMED as Chief Technology Officer of its Advanced Surgical business, continuing his work in the field.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2015 | $265M | $265M | Conmed | — |
| EARLY VCOther financing | Mar 2015 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for SurgiQuest is 510 monthly website visits. SurgiQuest's team declined 47.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
SurgiQuest in the Orange ecosystem
The SurgiQuest office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
RC Capital
Fletcher Spaght Ventures
California Technology Ventures- ACAphelion Capital
Presidio Partners
Ares Capital
Other known investors1 additional known investor
Conmed
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SurgiQuest on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SurgiQuest’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









